Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05TIB
|
||||
| Former ID |
DAP000342
|
||||
| Drug Name |
Trospium
|
||||
| Synonyms |
Spasmex; Spasmoplex; Trosec; Trospium chloride; IP-631; Regurin (TN); Sanctura (TN); Spasmex (TN); Spasmoplex (TN); Trosec (TN); Trospium chloride (JAN/USAN/INN); Spiro(8-azoniabicyclo(3.2.1)octane-8,1'-pyrrolidinium), 3-hydroxy-, chloride, benzilate; Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl 2-hydroxy-2,2-diphenylacetate; Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl 2-hydroxy-2,2-diphenylacetate chloride; 3-Hydroxyspiro(8-azoniabicyclo(3.2.1)octane-8,1'-pyrrolidinium) chloride benzilate; 6,10-Ethano-5-azoniaspiro(4.5)decan-8-ol, chloride, benzilate; 8-Benziloyloxy-6,10-ethano-5-azoniaspiro(4.5)decane chloride
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Overactive bladder disorder; Spasm [ICD9: 188, 596.51, 728.85; ICD10:C67, N32.81, R25.2] | Approved | [1], [2], [3], [4], [5] | ||
| Therapeutic Class |
Parasympatholytics
|
||||
| Company |
Allergan Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C25H30NO3+
|
||||
| InChI |
InChI=1S/C25H30NO3/c27-24(25(28,19-9-3-1-4-10-19)20-11-5-2-6-12-20)29-23-17-21-13-14-22(18-23)26(21)15-7-8-16-26/h1-6,9-12,21-23,28H,7-8,13-18H2/q+1
|
||||
| InChIKey |
OYYDSUSKLWTMMQ-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 10405-02-4
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| SuperDrug ATC ID |
G04BD09
|
||||
| SuperDrug CAS ID |
cas=010405024
|
||||
| Target and Pathway | |||||
| Target(s) | Muscarinic acetylcholine receptor M5 | Target Info | Antagonist | [6] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Cholinergic synapse | |||||
| Regulation of actin cytoskeleton | |||||
| PANTHER Pathway | Alzheimer disease-amyloid secretase pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Reactome | Muscarinic acetylcholine receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| Calcium Regulation in the Cardiac Cell | |||||
| Regulation of Actin Cytoskeleton | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4. | ||||
| REF 2 | Trospium chloride: the European experience. Expert Opin Pharmacother. 2006 Jul;7(10):1373-80. | ||||
| REF 3 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 021595. | ||||
| REF 4 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7480). | ||||
| REF 5 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 6 | Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.